Biomarker ID | 97 |
PMID | 15666387 |
Year | 2005 |
Biomarker | Thymosin b15 (Tb15) |
Biomarker Basis | Concentration Based (ng/dl)/(μg/mg) |
Biomolecule | Protein |
Source | Urine |
Subjects | Humans |
Regulation | Upregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | OR: 8.3 (95% CI: 2.7-26.1) |
Effect on Pathways | Pathways Include:-PAK5 human kinase ARCHS4 coexpression, EPHA4 human kinase ARCHS4 coexpression,ACVR2B human kinase ARCHS4 coexpression,MAP3K13 human kinase ARCHS4 coexpression,EPHA7 human kinase ARCHS4 coexpression |
Experiment | Untreated Prostate Cancer Vs Controls |
Type of Biomarker | Diagnostic |
Cohort | Patients with Prostate Cancer, including 61 patients prior to therapy (PCa untreated), 46 patients who received a Radical Prostatectomy and no PSA faliure for 2 years, and 14 patients receiving androgen deprivation therapy (ADT) for metastatic disease. Control Group consisted of 52 healthy subjects out of which 15 had history of nephrolithiasis but no active disease. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | ELISA |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | TMSB15A |